Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlobeStar Therapeutics Corp GSTC

Healthcare Biotechnology
GlobeStar Therapeutics Corporation (GlobeStar Therapeutics) is a clinical-stage pharmaceutical company. The Company is focused on introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The Company owns the global license from the inventors, who are based in Italy.

Recent & Breaking News (GREY:GSTC)

Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials

ACCESS Newswire March 28, 2024

GlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment

ACCESS Newswire November 2, 2023

Globestar Therapeutics Enters into Definitive Agreement with SMI Healthcare to Manage Clinical Trial, Regulatory Filings, Manufacturing and Sales in MEA Region for Multiple Sclerosis Treatment

ACCESS Newswire September 28, 2023

Globestar Therapeutics Enters into MOU with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis Treatment

ACCESS Newswire June 14, 2023

GlobeStar Therapeutics Corporation Update on Recent Activity

ACCESS Newswire August 2, 2022

CORRECTING and REPLACING GlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking Contract

ACCESS Newswire March 1, 2022

GlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking Contract

ACCESS Newswire March 1, 2022

GlobeStar Therapeutics Corporation Addresses the Potential Link Between Neurodegenerative Disease and Parkinson's Disease

ACCESS Newswire February 4, 2022

GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets

ACCESS Newswire October 11, 2021

GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.

ACCESS Newswire October 4, 2021

GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis

ACCESS Newswire September 20, 2021

AngioSoma, Inc. Is Officially GlobeStar Therapeutics Corporation.

ACCESS Newswire July 6, 2021

Angiosoma, Inc., Soon to Be Globestar Therapeutics Corporation, Welcomes Kaushik Srinivasan, CEO, Radiant Health to the Medical Advisory Board

ACCESS Newswire July 1, 2021

AngioSoma, Inc., Soon To Be GlobeStar Therapeutics Corporation, Welcomes Dr. Michael Lewis, MD, MPH, MBA, FACPM, FACN To The Medical Advisory Board

ACCESS Newswire June 22, 2021

AngioSoma, Inc., Soon To Be GlobeStar Therapeutics Corporation, Retains Sichenzia Ross Ference, LLP As Outside Securities Counsel

ACCESS Newswire June 9, 2021

AngioSoma, Inc. Is Pleased To Welcome Robert Chicoski, CPA As Our New Chief Financial Officer and Treasurer

ACCESS Newswire May 12, 2021

AngioSoma, Inc. Is Pleased To Welcome Darryl Morris As A Strategic Economic Advisor

ACCESS Newswire May 11, 2021

AngioSoma, Inc. Is Pleased To Welcome Dr. Leonard Wisneski, MD, FACP As The Medical Advisory Board Chairman

ACCESS Newswire May 4, 2021

AngioSoma, Inc. Is Pleased To Welcome Steven F. Penderghast To Its Board Of Directors

ACCESS Newswire April 21, 2021

AngioSoma, Inc. Adds David Croom As Executive Vice President

ACCESS Newswire April 20, 2021